CHICAGO — Precision medicine in lung cancer is making a big impact at this year’s ASCO meeting. Rare mutations in lung tumors discovered through genetic screening are leading to the development of highly targeted drugs. And these drugs are shrinking tumors in patients not helped by current treatments.

Two case studies: A drug called BLU-667 from the biotech Blueprint Medicines (BPMC) caused tumors to shrink in 60% of patients with lung tumors containing an alteration to a gene called RET. These patients entered the clinical trial after standard chemotherapy stopped working.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy